Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease

scientific article published on 01 February 1997

Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID9028312

P50authorSteven RosenbergQ2347448
P2093author name stringHorning SJ
Hoppe RT
Yuen AR
Halpern JD
P433issue3
P304page(s)814-822
P577publication date1997-02-01
P1433published inBloodQ885070
P1476titleComparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease
P478volume89

Reverse relations

cites work (P2860)
Q51742964A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.
Q39195424Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience.
Q74234766CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma
Q37146056Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up
Q27022992Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant
Q35117413Current therapies in Hodgkin's disease
Q34095620Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma
Q53080371Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.
Q53315058Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma.
Q41909027High-Dose Therapy and Autologous Hematopoietic Progenitor Cells Transplantation for Recurrent or Refractory Hodgkin's Lymphoma: Analysis of King Hussein Cancer Center Results and Prognostic Variables
Q37577385High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
Q37238152High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience
Q35735986Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report
Q42742589Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma
Q34501005Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas
Q42433067Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution
Q37254806Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure
Q34064220Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma
Q34495333Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography
Q36404763Role of hematopoietic stem cell transplantation in relapsed/refractory hodgkin lymphoma
Q35930635Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy
Q90413312Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
Q37411665Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study
Q34214895Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits?

Search more.